Sanofi SA (SNY) reports robust sales growth driven by Dupixent and vaccines, while planning a significant share buyback to ...

Deutsche Bank (ETR:DBKGn) analyst Emmanuel Papadakis upgraded Sanofi (NASDAQ:SNY) stock from Sell to Hold and increased the ...

Sanofi (NASDAQ:SNY) announced on Thursday that it plans to repurchase €5 billion ($5.21 billion) worth of shares this year and may take a more active approach to acquisitions in the near term. The ...

Deutsche Bank has upgraded Sanofi (NASDAQ:SNY) to hold from sell, citing the company's Q4 earnings report. The investment ...

Sanofi (SAN:FP) (NASDAQ: NASDAQ:SNY) saw its price target increased by Leerink Partners from €113.00 to €120.00, while the firm maintained an Outperform rating on the company's shares. Currently ...

Dupixent continues leading among Sanofi’s portfolio, and it’s poised for up to $20 billion in peak sales. Read my SNY ...

Geneos Wealth Management Inc. decreased its position in Sanofi (NASDAQ:SNY – Free Report) by 2.1% in the 4th quarter, Holdings Channel.com reports. The fund owned 10,223 shares of the company’s stock ...

Fifth Third Bancorp reduced its stake in Sanofi (NASDAQ:SNY – Free Report) by 9.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange ...

Sanofi (NASDAQ:SNY – Get Free Report) was the target of unusually large options trading on Monday. Traders acquired 2,013 put options on the company. This is an increase of approximately 68% compared ...

Sanofi (NASDAQ:SNY) reported robust financial results for the fourth quarter of 2024, driven by significant sales growth and a solid increase in earnings per share (EPS). The company's net sales rose ...

Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant Approval based on positive results from the IMROZ phase 3 study ...

Sanofi (NASDAQ:SNY – Free Report) – Investment analysts at Zacks Research raised their Q3 2025 EPS estimates for Sanofi in a report released on Wednesday, January 22nd. Zacks Research analyst K.